Chemokine Therapeutics Announces Issuance of Two New U.S. Patents
Posted on: Wednesday, 28 May 2008, 09:00 CDT
Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that it has been granted two U.S. Patents (No's 7,354,899 and 7,368,425).
Patent No. 7,354,899 entitled "Methods of treating Autoimmune Diseases Comprising Administering CXCR4 Antagonists" is related to the treatment of a wide range of autoimmune and inflammatory diseases such as multiple sclerosis, arthritis and psoriasis. The patent was filed based on considerable evidence that the pathway, involving the SDF-1 chemokine and its CXCR4 receptor, plays a significant role in autoimmune diseases.
Patent No. 7,368,425 entitled "Cyclic Peptides for Modulating Growth of Neo-Vessels and Their Use in Therapeutic Angiogenesis" is related to the use of chemokine SDF-1 to induce blood vessel growth to treat cardiovascular, peripheral vascular and other vascular diseases. This chemokine also has the potential for activity in tissue injuries such as wound healing.
"These patents help strengthen the Company's growing proprietary position in chemokine-based therapies which seek to address unmet medical needs," said Dr. Donald Wong, Vice President, Drug Development.
About Chemokine Therapeutics Corp. (TSX: CTI)(OTCBB: CHKT)
Chemokine Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling proteins that play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.
Contacts: Chemokine Therapeutics Corp. Mr. Don Evans Vice President, Corporate Communications (604) 822-0305 or 1-888-822-0305 (604) 822-0302 (FAX) Email: devans@chemokine.net Website: www.chemokine.net
SOURCE: Chemokine Therapeutics Corp.
Source: MARKET WIRE
Related Articles
- Chemokine Therapeutics Announces Issuance of U.S. Patent
- Chemokine Therapeutics Announces Liver Cancer Data Presented at the AACR Meeting on Its Lead Compound, CTCE-9908
- Chemokine Therapeutics Announces Positive Data Presented at the AACR Annual Meeting on Lead Product Candidate CTCE-9908
- Dr. Anthony Tolcher to Speak at the AACR Annual Meeting on Chemokine Therapeutic's Lead Drug Candidate CTCE-9908
- Chemokine Therapeutics Receives Approval From FDA to Commence Phase II Study
- Research and Markets: Gain Insight into the Current Product Pipeline at Chemokine Therapeutics Corp. With New Report
- Chemokine Therapeutics Corp.: Two Additional Abstracts Accepted for Presentation at the Upcoming Molecular Targets and Cancer Therapeutics International Conference
- Chemokine Therapeutics to Present at BioContact Annual Global Healthcare Conference
- Chemokine Therapeutics Files for a Public Offering of Units
 |
 |
User Comments (0)
RSS Feeds